Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

George J Netto; Mahul B Amin; Eva M Compérat; Anthony J Gill; Arndt Hartmann; Holger Moch; Santosh Menon; Maria R Raspollini; Mark A Rubin; John R Srigley; Puay Hoon Tan; Satish K Tickoo; Toyonori Tsuzuki; Samra Turajlic; Ian Cree; Daniel M Berney

doi:10.1016/j.eururo.2022.09.015

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

Eur Urol. 2023 Apr;83(4):301-303. doi: 10.1016/j.eururo.2022.09.015. Epub 2022 Oct 4.

Authors

George J Netto¹, Mahul B Amin², Eva M Compérat³, Anthony J Gill⁴, Arndt Hartmann⁵, Holger Moch⁶, Santosh Menon⁷, Maria R Raspollini⁸, Mark A Rubin⁹, John R Srigley¹⁰, Puay Hoon Tan¹¹, Satish K Tickoo¹², Toyonori Tsuzuki¹³, Samra Turajlic¹⁴, Ian Cree¹⁵, Daniel M Berney¹⁶

Affiliations

¹ Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: [email protected].
² Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA.
³ Department of Pathology, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria.
⁴ Sydney Medical School, University of Sydney, Sydney, Australia; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, Australia; Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia.
⁵ Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
⁶ Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
⁷ Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
⁸ Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy.
⁹ Department for BioMedical Research, Bern Center for Precision Medicine, University of Bern and Inselspital, Bern, Switzerland.
¹⁰ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
¹¹ Division of Pathology, Singapore General Hospital, Singapore.
¹² Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹³ Department of Surgical Pathology, Aichi Medical University Hospital, Nagakut, Japan.
¹⁴ Francis Crick Institute and Royal Marsden NHS Foundation Trust, London, UK.
¹⁵ International Agency for Research on Cancer, World Health Organization, Lyon, France.
¹⁶ Barts Cancer Institute, Queen Mary University of London and Department of Cellular Pathology, Barts Health NHS Trust, London, UK.

PMID: 36202687
DOI: 10.1016/j.eururo.2022.09.015

Abstract

We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.

Publication types

Editorial

MeSH terms

Adenocarcinoma* / pathology
Humans
Male
Neoplasm Grading
Prostate / pathology
Prostate-Specific Antigen
Prostatic Neoplasms* / pathology

Substances

Prostate-Specific Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding